13.95
+1.82%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Polaris Group LLC
Its shares trade on Taiwan Stock Exchange under the ticker 6550.TW. It has been listed since 15 February 2016. In the fiscal year to 31 December 2025, it reported revenue of TWD 40.6m and a net loss of TWD 3.95bn. At that date it held total assets of TWD 8.17bn and shareholders' equity of TWD 5.30bn.
Polaris Group engages in the research and development of biotechnology drugs. The Company’s core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 15 Feb 2016
- Website
- polarispharma.com/?lang=en ↗
Leadership
Pay as last reported
- Mr. Jaan-Pyng HsuChairman of the Board, Chief Executive Officer, since 2023TWD 4.7m
- Carrie ChangChief Financial Officer, Head of Finance
- Mr. John BomalaskiExecutive Deputy General Manager, since 2006
- Mr. Chris HuxsollDeputy General Manager-Production
- Ms. Amanda JohnstonDeputy General Manager-Clinical Affairs
- Elaine ChenCorporate Governance Officer
- Chieh-Hsiu WuHead of Accounting
- Mr. Kevin WuChief Information Security OfficerTWD 400,000
- Mr. Shyan-Tser ChenDirectorTWD 1.3m
- Mr. Kao-Chung TsaiDirectorTWD 376,000
- Mr. Ying-Chen ChaoIndependent DirectorTWD 1.6m
- Kwok-Wah TsangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Polaris Group LLC focuses on biotechnology drug R&D with ADI-PEG 20 in late-stage clinical trials.
- The company's ADI-PEG 20 targets multiple cancer indications including hepatocellular carcinoma and pancreatic cancer.
- The ADI-PEG 20 is a biologic drug combining arginine deiminase and polyethylene glycol with a 20,000 molecular weight.
Weaknesses
- The company's ADI-PEG 20 is still in clinical trials without commercialization status.
- The source description treats untrusted facts as factual without verification.
- The company operates in a highly regulated biotechnology sector with high R&D risks.
Opportunities
- ADI-PEG 20's late-stage development could lead to market entry for multiple cancer treatments.
- The broad cancer indications covered by ADI-PEG 20 may attract diverse investor interest.
- The company's focus on biologic drugs aligns with growing healthcare innovation trends.
Threats
- Clinical trial failures could delay or halt ADI-PEG 20's development and commercialization.
- Regulatory hurdles in biotechnology drug approval may increase development timelines.
- Competition from other biotech firms developing similar cancer treatments poses a risk.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.